PBM
PHAT icon

Propel Bio Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Propel Bio Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.35M Buy
841,272
+100,354
+14% +$1.27M 5.9% 3
2025
Q4 		$12.3M Buy
740,918
+187,991
+34% +$2.68M 10.49% 3
2025
Q3 		$6.51M Sell
552,927
-370,000
-40% -$3.82M 6.51% 6
2025
Q2 		$8.85M Sell
922,927
-212,000
-19% -$1.17M 10.74% 4
2025
Q1 		$7.12M Buy
1,134,927
+145,000
+15% +$880K 8.27% 4
2024
Q4 		$8.04M Buy
989,927
+120,000
+14% +$1.49M 7.98% 6
2024
Q3 		$15.7M Hold
869,927
– – 9.12% 3
2024
Q2 		$8.96M Hold
869,927
– – 5.81% 6
2024
Q1 		$9.24M Buy
869,927
+426,880
+96% +$3.63M 5.38% 6
2023
Q4 		$4.05M Buy
+443,047
New +$3.82M 3.35% 8

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Propel Bio Management's PHAT Position: Q1 2026 in Review

Propel Bio Management increased its Phathom Pharmaceuticals (PHAT) stake by 14% in Q1 2026, buying an estimated $1.27M and bringing the position to 841,272 shares worth $9.35M. The position accounts for 5.9% of the portfolio, ranked #3.

Propel Bio Management first reported a position in PHAT in Q4 2023 and has held it in 10 quarters since. The position peaked at $15.7M in Q3 2024. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Propel Bio Management held 841,272 shares of Phathom Pharmaceuticals worth $9.35M as of Q1 2026.
  • Propel Bio Management bought 100,354 Phathom Pharmaceuticals shares in Q1 2026, an estimated $1.27M.
  • Phathom Pharmaceuticals made up 5.9% of Propel Bio Management's portfolio in Q1 2026, its #3 holding.
  • Propel Bio Management first reported a position in Phathom Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • Propel Bio Management's Phathom Pharmaceuticals position peaked at $15.7M in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Propel Bio Management's 13F filing for Q1 2026, filed 14 May 2026.